Plasma circulating microRNAs in patients with stable coronary artery disease – Impact of different cardiovascular risk profiles and glomerular filtration rates
Background and aim: Plasma circulating microRNA-126, -145, and -155 are associated with vascular remodelling, atherosclerotic lesion formation and plaque vulnerability. In this study, we evaluated the levels of plasma circulating miRNAs in patients with stable coronary artery disease, different cardiovascular risk profiles and different glomerular filtration rates.
Methods: Forty patients with stable coronary artery disease (CAD) admitted for elective percutaneous coronary intervention (PCI) were enrolled in a prospective study. Before PCI, fasting blood samples were obtained to evaluate clinical parameters and microRNA (miRNA)-126 and miRNA-155 expression. The glomerular filtration rate (GFR) was calculated by the MDRD and CKD-EPI formulas, and the severity of CAD was calculated according to the SYNTAX score. All these parameters were correlated with miRNAs.
Results:The association between miRNA levels and clinical characteristics was evaluated. The expression of miRNA-126 positively correlated with a higher SYNTAX score (r=0.337; p=0.034); however, no significant correlations between miR-126, GFR and clinical characteristics were observed. Higher plasma levels of miRNA-155 correlated with increased levels of triglycerides (r=0.317; p=0.049), C-peptide (r=0.452; p=0.011), and the HOMA index (r=0.447; p=0.012) and a higher body mass index (r=0.385; p=0.015). GFR and miRNA-155 (MDRD - Rho=0.353; p=0.027. CKD-EPI - Rho=0.357; p=0.026) were found to have a moderate correlation, although miRNA-155 had no correlation with the SYNTAX score.
Conclusion: Plasma circulating miRNA-126 levels were increased in patients with severe atherosclerosis as determined by the SYNTAX score. Elevated miRNA-155 expression was observed in patients with stage 1 GFR but was lower in patients with stage 2 and 3 GFR. Plasma circulating miRNA-155 had positive correlations with higher levels of BMI, HOMA index, C-peptide and triglycerides.
Relevance for patients: Although further investigations are needed to confirm the role of miRNA-155 and miRNA-126, they may serve as potential biomarkers detecting severity of CAD, lowering of kidney function and metabolic syndrome.
[1] He L, Hannon GJ. MicroRNAs: Small RNAs with a Big Role in Gene Regulation. Nat Rev Genet 2004;5:522-31.
[2] Lee RC, Feinbaum RL, Ambros V. The C. Elegans Heterochronic Gene Lin-4 Encodes Small RNAs with Antisense Complementarity to Lin-14. Cell 1993;75:843-54.
[3] Wahid F, Shehzad A, Khan T, Kim YY. MicroRNAs: Synthesis, Mechanism, Function, and Recent Clinical Trials. Biochim Biophys Acta 2010;1803:1231-43.
[4] Andreou I, Sun X, Stone PH, Edelman ER, Feinberg MW. miRNAs in Atherosclerotic Plaque Initiation, Progression, and Rupture. Trends Mol Med 2015;21:307-18.
[5] Wei Y, Nazari-Jahantigh M, Neth P, Weber C, Schober A. MicroRNA-126,-145, and-155: A Therapeutic Triad in Atherosclerosis? Arterioscler Thromb Vasc Biol 2013;33:449-54.
[6] Feinberg MW, Moore KJ. MicroRNA Regulation of Atherosclerosis. Circ Res 2016;118:703-20.
[7] Lovren F, Pan Y, Quan A, Singh KK, Shukla PC, Gupta N, et al. MicroRNA-145 Targeted Therapy Reduces Atherosclerosis. Circulation 2012;126 11 Suppl 1:S81-90.
[8] Bruen R, Fitzsimons S, Belton O. miR-155 in the Resolution of Atherosclerosis. Front Pharmacol 2019;10:463.
[9] O’Donnell CJ, Elosua R. Factores de Riesgo Cardiovascular. Perspectivas Derivadas del Framingham Heart Study [Cardiovascular risk factors. Insights from Framingham Heart Study]. Rev Esp Cardiol 2008;61:299-310.
[10] Buie JN, Goodwin AJ, Cook JA, Halushka PV, Fan H. The Role of miRNAs in Cardiovascular Disease Risk Factors. Atherosclerosis 2016;254:271-81.
[11] Major RW, Cheng MR, Grant RA, Shantikumar S, Xu G, Oozeerally I, et al. Cardiovascular Disease Risk Factors in Chronic Kidney Disease: A Systematic Review and MetaAnalysis. PLoS One 2018;13:e0192895.
[12] Ghany MA, Wageeh M, Roshdy S. CRT-142 Correlation between Indices of Kidney Function (Estimated Glomerular Filtration Rate and Proteinuria) and Syntax Score in Non-Diabetic Chronic Kidney Disease Patients. JACC 2014;7:S21.
[13] Eisen A, Hoshen M, Balicer RD, Reges O, Rabi Y, Leibowitz M, et al. Estimated Glomerular Filtration Rate Within the Normal or Mildly Impaired Range and Incident Cardiovascular Disease. Am J Med 2015;128:1015-22.e2.
[14] European Association for Cardiovascular Prevention and Rehabilitation, Reiner Z, Catapano AL, De Backer G, Graham I, Taskinen MR, et al. ESC/EAS Guidelines for the Management of Dyslipidaemias: The Task Force for the Management of Dyslipidaemias of the European SOCIETY of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Eur Heart J 2011;32:1769-818.
[15] Bentzon JF, Otsuka F, Virmani R, Falk E. Mechanisms of Plaque Formation and Rupture. Circ Res 2014;114:1852-66.
[16] Fichtlscherer S, de Rosa S, Fox H, Schwietz T, Fischer A, Liebetrau C, et al. Circulating microRNAs in Patients with Coronary Artery Disease. Circ Res 2010;107:677-84.
[17] Li HY, Zhao X, Liu YZ, Meng Z, Wang D, Yang F, et al. Plasma MicroRNA-126-5p is Associated with the Complexity and Severity of Coronary Artery Disease in Patients with Stable Angina Pectoris. Cell Physiol Biochem 2016;39:837-46.
[18] Sun X, Zhang M, Sanagawa A, Mori C, Ito S, Iwaki S, et al. Circulating microRNA-126 in Patients with Coronary Artery Disease: Correlation with LDL Cholesterol. Thromb J 2012;10:16.
[19] Lu H, Daugherty A. Atherosclerosis. Arterioscler Thromb Vasc Biol 2015;35:485-91.
[20] Knoka E, Trusinskis K, Mazule M, Briede I, Crawford W, Jegere S, et al. Circulating Plasma microRNA-126, microRNA-145, and microRNA-155 and their Association with Atherosclerotic Plaque Characteristics. J Clin Transl Res 2020;5:60-7.
[21] Zernecke A, Bidzhekov K, Noels H, Shagdarsuren E, Gan L, Denecke B, et al. Delivery of microRNA-126 by Apoptotic Bodies Induces CXCL12-Dependent Vascular Protection. Sci Signal 2009;2:ra81.
[22] Curtale G, Rubino M, Locati M. MicroRNAs as Molecular Switches in Macrophage Activation. Front Immunol 2019;10:799.
[23] Longo M, Zatterale F, Naderi J, Parrillo L, Formisano P, Raciti GA, et al. Adipose Tissue Dysfunction as Determinant of Obesity-Associated Metabolic Complications. Int J Mol Sci 2019;20:2358.
[24] Karkeni E, Astier J, Tourniaire F, El Abed M, Romier B, Gouranton E, et al. Obesity-associated Inflammation Induces microRNA-155 Expression in Adipocytes and Adipose Tissue: Outcome on Adipocyte Function. J Clin Endocrinol Metab 2016;101:1615-26.
[25] Zand H, Morshedzadeh N, Naghashian F. Signaling Pathways Linking Inflammation to Insulin Resistance. Diabetes Metab Syndr 2017;11 Suppl 1:S307-9.
[26] Engin AB, Engin A. Obesity and Lipotoxicity. Berlin: Springer; 2017. p. 960.
[27] Muendlein A, Geiger K, Leiherer A, Saely CH, Fraunberger P, Drexel H. Evaluation of the Associations between Circulating microRNAs and Kidney Function in Coronary Angiography Patients. Am J Physiol Renal Physiol 2020;312:F315-21.
[28] Le TH, Kim HS, Allen AM, Spurney RF, Smithies O, Coffman TM. Physiological Impact of Increased Expression of the AT1 Angiotensin Receptor. Hypertension 2003;42:507-14.
[29] Chen NX, Kiattisunthorn K, O‘Neill KD, Chen X, Moorthi RN, Gattone VH 2nd, et al. Decreased microRNA is Involved in the Vascular Remodeling Abnormalities in Chronic Kidney Disease (CKD). PLoS One 2013;8:e64558.
[30] Neal CS, Michael MZ, Pimlott LK, Yong TY, Li JY, Gleadle JM. Circulating microRNA Expression is Reduced in Chronic Kidney Disease. Nephrol Dial Transplant 2011;26:3794-802.
[31] Fourdinier O, Schepers E, Metzinger-Le Meuth V, Glorieux G, Liabeuf S, Verbeke F, et al. Serum Levels of miR-126 and miR-223 and Outcomes in Chronic Kidney Disease Patients. Sci Rep 2019;9:4477.
[32] Maitrias P, Metzinger-Le Meuth V, Nader J, Reix T, Caus T, Metzinger L. The Involvement of miRNA in Carotid-Related Stroke. Arterioscler Thromb Vasc Biol 2017;37:1608-17.
[33] Roberts TC, Coenen-Stass AM, Wood MJ. Assessment of RT-qPCR Normalization Strategies for Accurate Quantification of Extracellular microRNAs in Murine Serum. PLoS One 2014;9:e89237.